P/E của cổ phiếu RIGL là bao nhiêu?

Rigel Pharmaceuticals Inc (RIGL) hiện giao dịch ở mức P/E 1.90 lần.

ROE của cổ phiếu RIGL là bao nhiêu?

Rigel Pharmaceuticals Inc có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 91.08%.

Tỷ suất cổ tức của RIGL là bao nhiêu?

Rigel Pharmaceuticals Inc có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của RIGL là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của RIGL ở mức 92/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu RIGL không?

Điểm AI Timing của RIGL là 67/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu RIGL thuộc ngành nào?

Rigel Pharmaceuticals Inc được xếp vào ngành Healthcare >> Biotechnology trên sàn NASDAQ

Cổ phiếu RIGL (NASDAQ) | RIGEL PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

RIGL AI Analysis Summary

Our AI summary for RIGL: Rigel Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 1.90, ROE of 91.08%, a dividend yield of 0.00%. Its financial Quality Score stands at 92/100 — fundamentals stronger than most of the market. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

RIGL

Rigel Pharmaceuticals Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 96

USD 38.70

1.27 (3.39%) Day Change

Watchlist Portfolio Compare Chart

1.90

P/E

0.11

D/E

91.1%

ROE

72.2%

ROA

0.00%

Div Yield

RIGEL PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 38.70 Price 1.27 (3.39%) Day Change	NEWS SCORE: 96

RIGL Chất lượng tổng thể của cố phiếu Xuất sắc ( Chất lượng = 92) và Thời điểm mua ...(Sign In to See)...

Loading chart...

92 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: Tăng trưởng ROE là âm trong năm ngoái.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

73%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	96
Magic Formula Rank by ROA	30 GREAT
Magic Formula Rank by ROE	30 GREAT
Magic Formula Rank by ROIC	88 GOOD
Price	38.70
PBV / Sector	1.73 / 44,022.72
Earning Per Share	20.35

PE / Sector	1.90 / 19.17 GREAT
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	12.11 M GREAT
Average 1W Daily Value	8.67 M

Yếu tố Kỹ thuật

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

43%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

68%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	121.51 / 98.24 GREAT
NPM Average (%) / Sector	37.16 / -1,697.63 GREAT
NPM Change Average (%) / Sector	243.71 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	72.18 / 185,260.96 GREAT
ROA Average (%) / Sector	17.86 / 36,684.70 GOOD
ROA Change Average (%) / Sector	92.61 / 422,221.66 GREAT
ROE (%) / Sector	91.08 / 243,762.23 GREAT
ROE Average (%) / Sector	246.88 / 48,758.47 GREAT
ROE Change Average (%) / Sector	85.56 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Chi tiết đăng ký

Analyze Date	2026-08-05 08:00:46
Symbol	RIGL
Name	RIGEL PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	18.50 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	692.53 / 9,586.08

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080

Phone: 650 624 1100

Website: https://www.rigel.com

Employees: 172

Sector: Healthcare >> Biotechnology

Description: Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.